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Oral epigallocatechin-3-gallate for
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Abstract: Recessive dystrophic epidermolysis bullosa (RDEB) is a rare genodermatosis with severe blistering. No
curative treatment is available. Scientific data indicated that epigallocatechin-3-gallate (EGCG), a green tea extract,
might improve the phenotype of RDEB patients. In a multicentre, randomized, crossover, double-blind, placebo-
controlled clinical trial, we evaluated a 4-month oral EGCG treatment regimen in 17 RDEB patients. We found that
EGCG treatment was not more effective than placebo in modified intention to treat and per protocol analysis (n = 16;
p = 0.78 and n = 10; p = 1 respectively). Tolerance was good. Specific organizational and technical difficulties of
controlled randomized double-blind trials in EB patients are discussed.
Trial registration: US National Institutes of Health Clinical Trial Register (NCT00951964).
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Recessive dystrophic epidermolysis bullosa (RDEB) is a
rare genodermatosis characterized by skin and mucosal
fragility due to mutations in the COL7A1 gene [1]. No
curative treatment is available [2]. It has been shown
that the level of activation of dermal metalloproteinases
(MMP) could modulate the phenotype in RDEB patients
[3–5] and that epigallocatechin-3-gallate (EGCG), a
green tea extract [6–8], is able to regulate this activity
in vitro and ex vivo [9].
We then evaluated the efficacy of oral EGCG to improve
skin impairment in RDEB patients in a multicentre,
randomized, crossover, double-blind, placebo-controlled
clinical trial. The trial was approved by the local ethics
committee and was registered in the Clinical Trial
Register (NCT00951964). Patients of both sexes, over
2 years of age, with generalized severe or intermediate
RDEB, confirmed by immunohistological analysis of skin
biopsy, were recruited. Patients received treatment or
placebo for 4 months, followed by a 2-month wash-out
period and then by the other treatment for 4 months
(Fig. 1). Dosage of EGCG treatment depended on the
patient’s weight (from 400 to 800 mg a day) (Additional
file 1, Supplementary Methods).
The main outcome was binary: success, defined as a
decrease ≥ 20 % in the number of new blisters per day
counted by patients at each dressing, upon 7 consecutive
dressings before the initial and final visit of each treat-
ment period, or failure of treatment. Secondary out-
comes were the affected cutaneous surface area, the
severity of mucosal impairment, skin fragility, itch and
the mean duration of healing measured on 3 new blis-
ters selected by patients in the first week of each period
of treatment (Additional file 2: Table S1). Adverse events
were collected by investigators at each visit. Assuming
an expected success rate of 30 % in the EGCG group
and 5 % in the placebo group, with 80 % power and 5 %
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type I error, we planned to include 22 patients. The main
outcome was analysed in a modified intention to treat
(mITT) and per protocol, secondary outcomes in a
mITT.
Findings
Seventeen patients were included in this study, mean age
19.4 years (±16.2 SD). One patient did not start treatment
and was not included in the mITT population (n = 16).
Only 10/16 patients were included in the per protocol ana-
lysis (available data for each visit in both treatment periods
for the main outcome). Eight patients/16 (50 %) had a de-
crease of at least 20 % in the mean number of new blisters
per day with EGCG and 5/16 (31 %) with placebo in the
mITT analysis. This difference was not statistically signifi-
cant (Prescott’s test, p = 0.78). Results were similar in per
protocol analysis (p = 1). Analyses of secondary outcomes
showed no difference between the 2 treatment periods
(Table 1) despite a dramatic reduction of the mean dur-
ation of wound in the EGCG group (-14.62 days ± 18.76)
compared to the placebo group (1.78 ± 14.65). Tolerance
was good with 26 and 16 adverse events in the EGCG and
placebo group respectively (p = 0.47) (Additional file 3:
Table S2).
Generalized DEB is a rare and severe genodermatosis.
Hence, evaluation of a new treatment in a controlled
randomized and double-blind trial is challenging. In this
study, even if fewer new blisters per day were observed
in the EGCG arm as compared with the placebo and the
mean duration of wound healing was shorter, we failed
to show a statistically significant difference. These disap-
pointing results can be explained by several limitations
of our study. First, under-enrolment and the high rate of
missing data for the main outcome are of important
concern. Low enrolment is a major drawback for studies
on all rare and severe diseases [10–13]. Indeed, despite
the active involvement of the DEBRA France patients’
support group and the main French centres for EB care,
together with the reimbursement of the patient’s travel
expenses, only 17 patients instead of the 22 planned
could be enrolled and only 10 completed the study.
Shorter studies with less visits and/or home evaluation
by a study nurse and/or international studies could im-
prove the patient recruitment and protocol adherence.
Moreover, factors influencing the severity of phenotype
in DEB are complex and not only related to the MMP
activity as recently shown [3, 14, 15]. Finally the high
rate of therapeutic success in the placebo group is intri-
guing, but seems to be frequent in the few controlled
versus placebo published studies on DEB [10–13]. The
variable course of DEB, depending on numerous factors
such as the weather, associated diseases and or/second-
ary complications or trauma, is well known. We tried to
minimize the impact of these factors by counting the
Fig. 1 Study design. Each patient has a 4 month period of treatment separated by a 2 month period of wash-out
Table 1 Statistical analysis of secondary outcomes
Evolution of score
(end of the period - beginning of the period)
Polyphenon E® Mean ± SD (N) Placebo Mean ± SD (N) p value
Surface area - 4.07 ± 7.62 (12) - 4.42 ± 9.84 (14) 0.93
Skin fragility - 0.90 ± 2.46 (12) - 0.64 ± 2.06 (14) 0.75
Mucosal involvement 0.55 ± 1.12 (8) 1.97 ± 1.64 (6) 0.07
Itch - 1.17 ± 3.53 (12) 0 ± 2.16 (14) 0.38
Mean duration of wound healing (days) -14.62 ± 18.76 (7) 1.78 ± 14.65 (9) 0.21
N number of patients, SD standard deviation
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number of new blisters per day averaged on seven con-
secutive dressings before each visit. However other out-
come measures like a validated EB severity score may be
more relevant. Analysis of the inclusion date of each pa-
tient did not support an influence of seasonal variation.
EGCG is a potentially interesting and safe treatment for
DEB patients. An international randomized, double-
blinded and placebo-controlled trial with targeted sub-
population is necessary.
Additional files
Additional file 1: Supplementary methods. (DOC 22 kb)
Additional file 2: Primary and secondary outcomes assessments.
(DOC 31 kb)
Additional file 3: Detailed adverse events for EGCG and placebo
treatment. * indicates the adverse events reported as severe by
investigators. (DOC 41 kb)
Abbreviations
DEB: dystrophic epidermolysis bullosa; EGCG: epigallocatechin-3-gallate;
mITT: modified intention to treat; MMP: metalloproteinases; RDEB: recessive
dystrophic epidermolysis bullosa; SD: standard deviation.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
Participation in designing study: CC, CR, EF, CB and J-PL. Participation in
generating data for the study: CC, EB, EB-L, CL, JM, PV, CB and J-PL. Participation
in gathering the data for the study: CC, CR, EF. Participation in the analysis of
the data: CC, CR, EF, CB and J-PL. Writing the majority of the original draft of the
paper: CC, EF, Participation in writing the paper: CC, CR, EF, EB, EB-L, CL, JM, PV,
CB and J-PL. Review the pertinent raw data on which the results and conclusions
of this study are based: CC, CR, EF. Approval the final version of this paper: CC, CR,
EF, EB, EB-L, CL, JM, PV, CB and J-PL.
Acknowledgment
Authors thank DEBRA France association for its implication in patient
recruitment for this study and their financial help for immunohistochemical
and molecular analyses.
Author details
1Reference Centre for Inherited Epidermolysis Bullosa, Archet 2 Hospital, Nice,
France. 2INSERM, U1081, CNRS, UMR7284, Institute for Research on Cancer
and Aging of Nice, University of Nice Sophia Antipolis, Nice, France.
3Department of Clinical Research and Innovation, University Hospital of Nice,
Nice, France. 4Reference Centre of Rare Skin Diseases, MAGEC 5, Saint Louis
Hospital, APHP, Paris, France. 5Reference Centre of Rare Skin Diseases,
Pellegrin Hospital, Bordeaux, France. 6Reference Centre of Rare Skin Diseases,
Larrey Hospital, Toulouse, France. 7Department of Dermatology, Bocage
Hospital, Dijon, France. 8Reference Centre of Rare Skin Diseases, MAGEC,
Necker Hospital, APHP, Institut Imagine, Paris, France. 9Université Paris
Descartes - Sorbonne Paris Cité, Paris, France.
Received: 25 September 2015 Accepted: 16 March 2016
References
1. Bruckner-Tuderman L. Dystrophic epidermolysis bullosa: pathogenesis and
clinical features. Dermatol Clin. 2010;28:107–14.
2. Hsu CK, Wang SP, Lee JY, et al. Treatment of hereditary epidermolysis
bullosa: updates and future prospects. Am J Clin Dermatol. 2014;15:1–6.
3. Titeux M, Pendaries V, Tonasso L, et al. A frequent functional SNP in the
MMP1 promoter is associated with higher disease severity in recessive
dystrophic epidermolysis bullosa. Hum Mutat. 2008;29:267–76.
4. Sawamura D, Sugawara T, Hashimoto I, et al. Increased gene expression of
matrix metalloproteinase-3 (stromelysin) in skin fibroblasts from patients
with severe recessive dystrophic epidermolysis bullosa. Biochem Biophys
Res Commun. 1991;174:1003–8.
5. Bodemer C, Tchen SI, Ghomrasseni S, et al. Skin expression of
metalloproteinases and tissue inhibitor of metalloproteinases in sibling
patients with recessive dystrophic epidermolysis and intrafamilial
phenotypic variation. J Invest Dermatol. 2003;121:273–9.
6. Singh BN, Shankar S, Srivastava RK. Green tea catechin, epigallocatechin-3-
gallate (EGCG): mechanisms, perspectives and clinical applications. Biochem
Pharmacol. 2011;82:1807–21.
7. Hu G, Zhang L, Rong Y, et al. Downstream carcinogenesis signaling pathways
by green tea polyphenols: a translational perspective of chemoprevention and
treatment for cancers. Curr Drug Metab. 2014;15:14–22.
8. Rhodes LE, Darby G, Massey KA, et al. Oral green tea catechin metabolites
are incorporated into human skin and protect against UV radiation-induced
cutaneous inflammation in association with reduced production of pro-
inflammatory eicosanoid 12-hydroxyeicosatetraenoic acid. Br J Nutr. 2013;
110:891–900.
9. Changotade SI, Assoumou A, Gueniche F, et al. Epigallocatechin gallate’s
protective effect against MMP7 in recessive dystrophic epidermolysis
bullosa patients. J Invest Dermatol. 2007;127:821–8.
10. Wally V, Kitzmueller S, Lagler F, et al. Topical diacerein for epidermolysis
bullosa: a randomized controlled pilot study. Orphanet J Rare Dis. 2013;8:69.
11. Lara-Corrales I, Parkin PC, Stephens D, et al. The efficacy of trimethoprim in
wound healing of patients with epidermolysis bullosa: a feasibility trial.
J Am Acad Dermatol. 2012;66:264–70.
12. Caldwell-Brown D, Stern RS, Lin AN, et al. Lack of efficacy of phenytoin in
recessive dystrophic epidermolysis bullosa. Epidermolysis Bullosa Study
Group. N Engl J Med. 1992;327:163–7.
13. Weiner M, Stein A, Cash S, et al. Tetracycline and epidermolysis bullosa
simplex: a double-blind, placebo-controlled, crossover randomized clinical
trial. Br J Dermatol. 2004;150:613–4.
14. Garza-Gomez J, Cerda-Flores RM, Gomez-Flores M, et al. An investigation
into the MMP1 gene promoter region polymorphism–1607 2G with
recessive dystrophic epidermolysis bullosa disease severity in northeastern
Mexican patients. Int J Dermatol. 2014;53:985–90.
15. Kern JS, Gruninger G, Imsak R, et al. Forty-two novel COL7A1 mutations and
the role of a frequent single nucleotide polymorphism in the MMP1
promoter in modulation of disease severity in a large European dystrophic
epidermolysis bullosa cohort. Br J Dermatol. 2009;161:1089–97.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Chiaverini et al. Orphanet Journal of Rare Diseases  (2016) 11:31 Page 3 of 3
